Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.56 (
caspase-3
)
35,750
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The biologic function as well as the mechanism of long noncoding RNAs (lncRNAs) in colorectal cancer (CRC) still remain largely unknown. Long noncoding RNA
FGD5
antisense RNA 1 (FGD5-AS1) has been reported to have a promotive effect on other human cancers, but its function in CRC still remains unknown. The expression levels of long noncoding RNA
FGD5
-AS1, CDCA7 mRNA, and miR-302e were assessed by RT-qPCR. The protein levels of CDCA7 were assessed by Western blot. The function of
FGD5
-AS1 was detected using cell viability assay, 5-ethynyl-2'-deoxyuridine (EdU) assay, transwell, and
caspase-3
activity assay. Additionally, the microRNAs (miRNAs) sponge potential of
FGD5
-AS1 was examined by RNA immunoprecipitation assay, RNA pull-down assay, and luciferase reporter assay.
FGD5
-AS1 was increased in colorectal cancer cell lines compared to normal cell lines. Inhibition of
FGD5
-AS1 suppressed cell proliferation, migration, invasion, and accelerated cell apoptosis in CRC.
FGD5
-AS1 competitively bound with miR-302e to modulate CDCA7. The inhibiting effects of
FGD5
-AS1 knockdown on CRC cell proliferation, migration, and invasion, and the promoting effects on CRC cell apoptosis could be revived by miR-302e suppression or CDCA7 upregulation. LncRNA
FGD5
-AS1 could promote CRC progression through sponging miR-302e and upregulating CDCA7.
FGD5
-AS1 might serve as a potential therapeutic target for CRC.
...
PMID:Long noncoding RNA FGD5-AS1 promotes colorectal cancer cell proliferation, migration, and invasion through upregulating CDCA7 via sponging miR-302e. 3133 96